The AccentCare acquisition, if closed, would expand revenue base by ~19% and add scale in key states. Monitor regulatory approval timeline and integration progress. Q3 results show consistent organic growth and margin expansion.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 4 $127.94entry
- T+1 · 12d ago −0.88%α +3.53% · $126.81
- T+5 · 6d ago −1.92%α −1.00% · $125.49
- T+8 · todayOpen
- T+20 · in 16d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Addus HomeCare reported Q3 2026 revenue of $387.7M (+7.0% YoY) and adjusted EPS of $1.83 (+17.3% YoY), exceeding consensus estimates of $388.7M and $1.79. The company also announced a definitive agreement to acquire AccentCare's personal care division for ~$275M, adding ~$280M in annualized revenue.
Key Financial Metrics
Key Facts
- Q3 2026 net service revenue $387.7M, up 7.0% YoY from $362.3M
- GAAP net income $28.6M ($1.54/diluted share) vs $22.8M ($1.24) YoY
- Adjusted net income per diluted share $1.83, up 17.3% YoY from $1.56
- Adjusted EBITDA $51.2M, up 13.5% YoY from $45.1M
- Operating cash flow $40.9M in Q3 2026
- Definitive agreement to acquire AccentCare personal care division for ~$275M, adding ~$280M annualized revenue
- Personal care segment revenue $301.0M (77.6% of total), organic growth 6.9%
- Hospice segment revenue $69.0M, organic ADC growth 4.3%
- Home health segment returned to organic revenue growth of 2.5%
- Cash $98.5M, bank debt $24.3M, $617.8M available under revolver as of Sep 30, 2026
Financial Impact
Revenue $387.7M, GAAP EPS $1.54, adjusted EPS $1.83, adjusted EBITDA $51.2M, operating cash flow $40.9M
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Personal Care | $301.0M | +9.2% |
| Hospice | $69.0M | +0.2% |
| Home Health | $17.7M | +0.4% |
Risk Factors
- AccentCare acquisition requires regulatory approvals and customary closing conditions
- Home health segment revenue still negative on a YTD basis (-2.3% organic)
- Hospice organic revenue growth of 4.1% slowed from prior year's 19.0%
- State reimbursement rate changes could impact personal care margins
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-034669 |
| Document: adus20261103_8k.htm | 0001437749-26-034669 |
| Document: 0001437749-26-034669-index-headers.html | 0001437749-26-034669 |
| Document: 0001437749-26-034669-index.html | 0001437749-26-034669 |
| Document: 0001437749-26-034669.txt | 0001437749-26-034669 |
| 8-K Data (Synthetic) | 0001437749-26-034669 |
Track record
19 reports on ADUS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +27.64% at T+60 after the Jun 11, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Insider Cluster Bearish 5/10 Entry $123.00 Now $124.61 −1.31% settles Feb 11
- Nov 10, 20266d ago Insider Cluster Neutral 4/10 Entry $125.49 Now $124.61 −0.70% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $125.49 Now $124.61 −0.70% settles Feb 9
- Nov 10, 20266d ago 144 Neutral 2/10 Entry $125.49 Now $124.61 −0.70% settles Feb 9
- Nov 9, 20267d ago 144 Neutral 3/10 Entry $126.29 Now $124.61 −1.33% settles Feb 8
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $122.42 Now $124.61 +1.79% settles Feb 5
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $122.42 Now $124.61 +1.79% settles Feb 5
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $122.42 Now $124.61 +1.79% settles Feb 5
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $122.42 Now $124.61 +1.79% settles Feb 5
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $122.42 Now $124.61 +1.79% settles Feb 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers